# V1 Empirics Check — deepseek/deepseek-v3.2 (Variant A)

**Model:** deepseek/deepseek-v3.2
**Variant:** A
**Date:** 2026-03-26T13:38:44.998938

---

**Referee Report: "The Treatment Door: Good Samaritan Laws and the Shift from Pain Opioids to Medication-Assisted Treatment in Medicaid"**

**1. Idea Fidelity**
The paper substantially deviates from the ambitious and well-specified research agenda outlined in the original Idea Manifest. The core shift is consequential: the paper abandons the study of *treatment admissions* (the stated research question) in favor of analyzing the *composition of Medicaid prescriptions*. This represents a different outcome, a different population (Medicaid enrollees vs. all individuals in treatment), and a different policy mechanism. The manifest’s central identification strategy—a triple-difference (DDD) using referral sources within the TEDS-A data to isolate the 911-to-ER-to-treatment pipeline—is completely absent. Instead, the paper substitutes a DDD comparing buprenorphine to pain opioid prescriptions, which tests a compositional shift but does not directly speak to the *entry* of new individuals into treatment. Key planned elements like using non-opioid admissions as a control, testing heterogeneity by immunity strength, and the “killer critique” discussion are missing. While the paper uses the suggested staggered DiD estimator (Callaway-Sant’Anna), the empirical approach no longer matches the original, compelling research question.

**2. Summary**
This paper investigates whether state-level Good Samaritan Laws (GSLs), which provide immunity for 911 callers during overdoses, alter the composition of Medicaid-reimbursed prescriptions, shifting them from opioid painkillers (oxycodone/hydrocodone) toward medication-assisted treatment (buprenorphine). Using a staggered difference-in-differences design on state-level data from 2006-2022, the author finds that GSLs cause a large, statistically significant increase in buprenorphine prescriptions relative to pain opioids, an effect that is complementary to Medicaid expansion.

**3. Essential Points**
The author must address these three critical issues for the paper to be viable for publication.

1.  **Misalignment Between Outcome and Causal Mechanism:** The proposed mechanism is that GSLs increase 911 calls, leading to ER encounters, which generate referrals and subsequent *treatment entry*. The outcome—aggregate state-level Medicaid buprenorphine prescriptions—is several steps removed from this mechanism and conflates intensive margin changes (existing patients filling more prescriptions) with extensive margin changes (new patients entering treatment). The paper provides no direct evidence that the observed prescription shift is driven by *new* patients entering the treatment system via the hypothesized ER pipeline. This weakens the causal claim and the paper's contribution to understanding the "treatment door."

2.  **Inadequate Handling of Medicaid Expansion Confounding:** The results show Medicaid expansion has a massive effect on buprenorphine volumes, dwarfing the simple GSL effect. The claim that the DDD design differences out this confounder is valid only if Medicaid expansion affected buprenorphine and pain opioid prescriptions *symmetrically*. This is a strong and untested assumption. Expansion likely had a disproportionate effect on buprenorphine access for the low-income OUD population. The author must formally test this symmetry (e.g., show parallel pre-trends for both drug types in expansion vs. non-expansion states) or, better, implement a triple-difference design that explicitly interacts GSL, Medicaid expansion, and drug type.

3.  **Weak and Indirect Evidence for the Proposed "Treatment Door" Pipeline:** The entire narrative hinges on a chain of events (GSL -> 911 -> ER -> Referral -> Buprenorphine Rx) for which only the final link is loosely observed. The paper lacks any "first-stage" evidence linking GSL adoption to increased ER visits or referrals in the Medicaid data. Furthermore, the finding that GSLs *reduce* pain opioid prescriptions (Table 3) is counterintuitive and undermines the story. If GSLs work by creating ER encounters for overdoses, why would prescriptions for pain management (an unrelated clinical pathway) decrease? This suggests the estimated compositional shift may be picking up a different, unspecified dynamic (e.g., general policy awareness reducing opioid prescribing), not the treatment pipeline.

**4. Suggestions**

**A. Re-align Analysis with the Original Research Question (Strongly Recommended):**
The most significant improvement would be to return to the TEDS-A analysis outlined in the manifest. This directly measures treatment *admissions* and allows for the powerful, mechanism-testing DDD using referral sources (healthcare vs. criminal justice). This approach is superior because:
*   **Face Validity:** Admissions are a clearer measure of treatment entry.
*   **Mechanism Test:** The referral-source DDD is a more direct test of the 911/ER pathway. A positive effect only for healthcare referrals would strongly support the proposed mechanism.
*   **Built-in Placebo:** Criminal justice referrals serve as a perfect placebo outcome.
*   **Addresses Confounding:** Using non-opioid admissions (alcohol) as an additional within-state control can help account for underlying trends in treatment system capacity.

**B. If Sticking with Prescription Data, Strengthen Identification and Mechanism:**
*   **First-Stage Analysis:** Use data on Medicaid-financed ER visits (available through T-MSIS or HCUP) to test if GSLs increase OUD-related ER encounters. This is a critical intermediate step.
*   **Extensive vs. Intensive Margin:** Use patient-level Medicaid data (T-MSIS) to distinguish between new patient initiations of buprenorphine and refills for existing patients. The theory is about the extensive margin.
*   **Refine the Control Group:** The pain opioid control is imperfect. Consider alternative within-Medicaid control groups: other chronic disease medications (e.g., insulin, antipsychotics) or SUD medications for other substances (e.g., naltrexone for alcohol). Test if the GSL effect is unique to buprenorphine.
*   **Formalize the Medicaid Expansion Challenge:** Implement a triple-difference design: `Y = α + β1(GSL) + β2(GSL*Bup) + β3(Expansion) + β4(Expansion*Bup) + β5(GSL*Expansion*Bup) + FE + ε`. The coefficient β5 would identify whether the GSL-induced compositional shift is different in expansion states.
*   **Address the Pain Opioid Puzzle:** Provide a credible explanation for why pain opioid prescriptions fall. Is it robust? Does it align with timing? Could it be an artifact of the log specification with high variance? Show raw levels.

**C. Improve Presentation and Robustness:**
*   **Event Study Graphs:** The paper references event study results but only in the appendix text. Main text figures showing event-study plots for the key specifications (simple DiD on buprenorphine, the DDD coefficient) are essential for assessing pre-trends and dynamic effects.
*   **Heterogeneity by Law Strength:** The manifest planned to test immunity strength. The PDAPS data codes this. This is a valuable test: stronger laws should have larger effects if the legal fear mechanism is correct.
*   **Sample Description:** Clarify the unit of observation. Is it `state-year` or `state-year-drug`? The narrative around 863 observations is confusing.
*   **Interpretation of Magnitudes:** A 2.6 log-point difference is enormous (> a 13-fold multiplicative difference). Is this plausible? Provide a back-of-the-envelope calculation linking potential increases in 911 calls to expected increases in buprenorphine patients to gauge reasonableness.
*   **Discussion Limitations:** The discussion should more forthrightly acknowledge that (a) Medicaid data excludes the uninsured and privately insured, limiting generalizability, and (b) the analysis cannot rule out that GSLs work by raising overall awareness of treatment options rather than specifically through the ER door.

**Conclusion:** The paper identifies an interesting empirical pattern but currently fails to credibly link it to the “treatment door” mechanism of Good Samaritan Laws. The identification is threatened by confounding from Medicaid expansion, and the outcome variable does not closely match the theoretical construct of interest. Implementing the suggestions above, particularly by shifting to the TEDS-A analysis, would transform the paper into a much stronger and more coherent contribution. In its current form, it is not yet ready for publication.
